Monod Bio
Monod Bio is revolutionizing life sciences tools and clinical diagnostics with AI-powered computational protein design. The company, a spin-out from the Baker Lab at the University of Washington's Institute for Protein Design, leverages advanced computational protein engineering to create highly modular biosensors, binders, and reporters. Their core products include NovoBody, LuxSit™ Pro, and NovoLISA, designed to enable faster, cheaper, and more effective analytical assays. Monod Bio's visionary founding team and state-of-the-art technology position them at the forefront of biosensor innovation.
Monod Bio
Monod Bio is revolutionizing life sciences tools and clinical diagnostics with AI-powered computational protein design. The company, a spin-out from the Baker Lab at the University of Washington's Institute for Protein Design, leverages advanced computational protein engineering to create highly modular biosensors, binders, and reporters. Their core products include NovoBody, LuxSit™ Pro, and NovoLISA, designed to enable faster, cheaper, and more effective analytical assays. Monod Bio's visionary founding team and state-of-the-art technology position them at the forefront of biosensor innovation.
TL;DR
Founded: 2021
Headquarters: Seattle, WA (spinout from UW Institute for Protein Design)
Core tech: AI-driven de novo protein design for biosensors, binders, and luciferase reporters
Flagship products: LuxSit Pro, NovoLISA, NovoBody
Notable investors: Matrix Capital Management; Bill & Melinda Gates Foundation
Total funding (reported): USD 27,250,000
Company Overview
Problem Domain
Life sciences research tools and in vitro diagnostics (biosensing and assay development).
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 25,000,000
Reported seed financing to advance biosensor platform.
USD 1,500,000
Grant to support diagnostics development (reported)
Investor Signal
“Matrix Capital Management; Bill & Melinda Gates Foundation; Washington Research Foundation; Sahsen Ventures; Pack Ventures; Global Health Investment Fund; Boom Capital Ventures; Cercano Management”